Clinical Ops Outsourcing The departure of CG Oncology's VP of Clinical Operations and ongoing late-stage trials suggest a need for external clinical operations support. Target CROs, CTMS/EDC vendors, central labs, and patient recruitment platforms to accelerate trial timelines and optimize data capture.

Launch Readiness With a successful upsized IPO and substantial funding but minimal revenue, CG Oncology is likely building commercial capacity; opportunities exist to engage HEOR and market access specialists for payer-ready value dossiers, pricing insight, and launch planning.

Urology Relationships Active participation at the American Urological Association conference and NMIBC focus signals strong potential for a formal KOL network, medical affairs program, and speaker bureau management to drive trial enrollment and future product adoption.

Data and Security The tech stack including AWS, JMP, and CISSP demonstrates maturity in data handling and security; there is demand for advanced biostatistics analytics, data integration across trials, and regulatory-compliant cloud infrastructure services.

Strategic Partnerships CG Oncology's public status, board expansion, and financing position create opportunities for strategic partnerships, licensing deals, or co-development arrangements with larger biopharma or CRO networks to fund expansion and commercialization in NMIBC.